2021 DORIS definition of remission in SLE: final recommendations from an international task force.

Abstract

OBJECTIVE:

To achieve consensus on a definition of remission in SLE (DORIS).

BACKGROUND:

Remission is the stated goal for both patient and caregiver, but consensus on a definition of remission has been lacking. Previously, an international task force consisting of patient representatives and medical specialists published a framework for such a definition, without reaching a final recommendation.

METHODS:

Several systematic literature reviews were performed and specific research questions examined in suitably chosen data sets. The findings were discussed, reformulated as recommendations and voted on.

RESULTS:

Based on data from the literature and several SLE-specific data sets, a set of recommendations was endorsed. Ultimately, the DORIS Task Force recommended a single definition of remission in SLE, based on clinical systemic lupus erythematosus disease activitiy index (SLEDAI)=0, Evaluator's Global Assessment <0.5 (0-3), prednisolone 5 mg/day or less, and stable antimalarials, immunosuppressives, and biologics.

CONCLUSION:

The 2021 DORIS definition of remission in SLE is recommended for use in clinical care, education, and research including clinical trials and observational studies.

• Authors: Ronald F van Vollenhoven, George Bertsias, Andrea Doria, David Isenberg, Eric Morand, Michelle A Petri, Bernardo A Pons-Estel, Anisur Rahman, Manuel Francisco Ugarte-Gil, Alexandre Voskuyl, Laurent Arnaud, Ian N Bruce, Ricard Cervera, Nathalie Costedoat-Chalumeau, Caroline Gordon, Frédéric A Houssiau, Marta Mosca, Matthias Schneider, Michael M Ward, Graciela Alarcon, Martin Aringer, Anka Askenase, Sang-Cheol Bae, Hendrika Bootsma, Dimitrios T Boumpas, Hermine Brunner, Ann Elaine Clarke, Cindy Coney, László Czirják, Thomas Dörner, Raquel Faria, Rebecca Fischer, Ruth Fritsch-Stork, Murat Inanc, Søren Jacobsen, David Jayne, Annegret Kuhn, Bernadette van Leeuw, Maarten Limper, Xavier Mariette, Sandra Navarra, Mandana Nikpour, Marzena Helena Olesinska, Guillermo Pons-Estel, Juanita Romero-Diaz, Blanca Rubio, Yehuda Schoenfeld, Eloisa Bonfá, Josef Smolen, Y K Onno Teng, Angela Tincani, Michel Tsang-A-Sjoe, Carlos Vasconcelos, Anne Voss, Victoria P Werth, Elena Zakharhova, Cynthia Aranow
• Journal: Lupus science & medicine (Lupus Sci Med) Vol. 8 Issue 1 (11 2021) ISSN: 2053-8790 [Print] England
• PMID: 34819388 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Chemical References

• Immunosuppressive Agents
• Prednisolone

Topics

• Humans
• Immunosuppressive Agents (therapeutic use)
• Lupus Erythematosus, Systemic (drug therapy)
• Prednisolone (therapeutic use)
• Remission Induction
• Severity of Illness Index